Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2013


#164549

58pages

Global Markets Direct

$ 2000

In Stock

 

Global Markets Direct’s, 'Hematopoietic Stem Cell Transplantation Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation. 

 

Hematopoietic Stem Cell Transplantation Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • A snapshot of the global therapeutic scenario for Hematopoietic Stem Cell Transplantation.
  • A review of the Hematopoietic Stem Cell Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Hematopoietic Stem Cell Transplantation pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Identify and understand important and diverse types of therapeutics under development for Hematopoietic Stem Cell Transplantation.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Hematopoietic Stem Cell Transplantation pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents


Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hematopoietic Stem Cell Transplantation Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Hematopoietic Stem Cell Transplantation 7
Hematopoietic Stem Cell Transplantation Therapeutics under Development by Companies 9
Hematopoietic Stem Cell Transplantation Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Hematopoietic Stem Cell Transplantation Therapeutics - Products under Development by Companies 13
Hematopoietic Stem Cell Transplantation Therapeutics - Products under Investigation by Universities/Institutes 14
Companies Involved in Hematopoietic Stem Cell Transplantation Therapeutics Development 15
Athersys, Inc. 15
GlaxoSmithKline plc 16
Celldex Therapeutics, Inc. 17
Pharmalink AB 18
Tokai Pharmaceuticals, Inc. 19
Polyphor Ltd. 20
Hematopoietic Stem Cell Transplantation - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
ronacaleret hydrochloride - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
MultiStem - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
busulfan - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
POL-6326 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
CDX-301 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Donor-Derived CMV-pp65 Peptide-Specific T Cells - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
TXA-127 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Hematopoietic Stem Cell Transplantation Therapeutics - Drug Profile Updates 38
Hematopoietic Stem Cell Transplantation Therapeutics - Discontinued Products 46
Hematopoietic Stem Cell Transplantation Therapeutics - Dormant Products 47
Hematopoietic Stem Cell Transplantation - Product Development Milestones 48
Featured News & Press Releases 48
Nov 12, 2012: Pharmalink Signs Manufacturing Agreement For Busulipo 48
Nov 05, 2012: Celldex To Present Phase I Data Of CDX-301 At American Society Of Hematology 54th Annual Meeting And Exposition 48
Sep 19, 2012: Gamida Cell Completes Enrollment For Phase I/II Study Of Second Pipeline Product Nicord For Hematological Malignancies 49
Sep 19, 2012: Unigene And Tarix Pharma Announce Completion Of Feasibility Study Of TXA127 49
Jul 09, 2012: Chimerix Announces BK Virus Data In Late-Breaking Poster Session At 24th International Congress Of Transplantation Society 50
Feb 01, 2012: Athersys Announces Phase I clinical trial Results Of MultiStem For Hematopoietic Stem Cell Transplant Support And Prevention Of Graft-Versus-Host Disease 51
Jan 17, 2012: Celldex Therapeutics Initiates Phase I Clinical Trial Of CDX-301 For Hematopoietic Stem Cell Transplantation 54
Nov 11, 2011: Chimerix Announces Late-Breaking Poster Presentation At Kidney Week 2011 Annual Meeting 54
Oct 17, 2011: Athersys Confirms Completion Of Patient Enrollment For Phase I Study Of MultiStem For Hematopoietic Stem Cell Transplant Support 55
Jul 26, 2011: TikoMed Receives Orphan Drug Designation For TM-400 From FDA 56
 

Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58


Number of Products Under Development for Hematopoietic Stem Cell Transplantation, H1 2013 7
Products under Development for Hematopoietic Stem Cell Transplantation - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Mid Clinical Stage Development, H1 2013 11
Comparative Analysis by Early Clinical Stage Development, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 14
Athersys, Inc., H1 2013 15
GlaxoSmithKline plc, H1 2013 16
Celldex Therapeutics, Inc., H1 2013 17
Pharmalink AB, H1 2013 18
Tokai Pharmaceuticals, Inc., H1 2013 19
Polyphor Ltd., H1 2013 20
Assessment by Monotherapy Products, H1 2013 21
Assessment by Stage and Route of Administration, H1 2013 23
Assessment by Stage and Molecule Type, H1 2013 25
Hematopoietic Stem Cell Transplantation Therapeutics - Drug Profile Updates 38
Hematopoietic Stem Cell Transplantation Therapeutics - Discontinued Products 46
Hematopoietic Stem Cell Transplantation Therapeutics - Dormant Products 47


Number of Products under Development for Hematopoietic Stem Cell Transplantation, H1 2013 7
Products under Development for Hematopoietic Stem Cell Transplantation - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Mid Clinical Stage Products, H1 2013 11
Early Clinical Stage Products, H1 2013 12
Assessment by Monotherapy Products, H1 2013 21
Assessment by Route of Administration, H1 2013 22
Assessment by Stage and Route of Administration, H1 2013 23
Assessment by Molecule Type, H1 2013 24
Assessment by Stage and Molecule Type, H1 2013 25